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Summary Opioid receptor binding was evaluated in parahippocampal cortex (PHC)
obtained from patients with intractable mesial temporal lobe epilepsy (MTLE) with
and without subacute high frequency electrical stimulation (HFS) in this brain area.
Mu, delta and nociceptin receptor binding was determined by autoradiography in PHC
of five patients (ESAE group) with MTLE history of 14.8  2.5 years and seizure
frequency of 11  2.9 per month, two of them (40%) with mesial sclerosis. This group
demonstrated antiepileptic effects following subacute HFS (130 Hz, 450 ms, 200—
400 mA), applied continuously during 16—20 days in PHC. Values were compared with
those obtained from patients with severe MTLE (history of 21.7  2.8 years and
seizure frequency of 28.2  14 per month) in whom electrical stimulation did not
induce antiepileptic effects (ESWAE group, n = 4), patients with MTLE in whom no
electrical stimulation was applied (MTLE group, n = 4) and autopsy material acquired
from subjects without epilepsy (n = 4 obtained from three subjects). Enhanced 3H-
DAMGO (MTLE, 755%; ESAE, 375%; ESWAE, 693%), 3H-DPDPE (MTLE, 242%; ESAE, 80%;
ESWAE, 346%) and 3H-nociceptin (MTLE, 424%; ESAE, 217%; ESWAE, 451%) binding was
detected in the PHC of all epileptic groups. However, tissue obtained from ESAE group
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47%, p < 0.05; 3H-nociceptin, 39.3%, p < 0.5) when compared with MTLE group. The
present results indicate that a high effectiveness to the antiepileptic effects induced
by HFS is associated with reduced opioid peptide binding.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
We previously reported that subacute high fre-
quency electrical stimulation (HFS) of the parahip-
pocampal cortex (PHC) significantly decreases the
number of interictal spikes at focus and abolished
clinical seizures in patients with intractable mesial
temporal lobe epilepsy (MTLE).1 Blockage of tem-
poral lobe epilepsy by PHC stimulation seems to be
due, at least in part, to an inhibitory process of the
stimulated area according with the following effects
observed in the patients receiving HFS: (a) an
increased threshold and decreased duration of the
PHC afterdischarge and depression of the PHC
evoked response recovery cycles, comparing the
same patients before versus after PHC stimulation;
(b) a single photon emission computed tomography
(SPECT) hypoperfusion of the hippocampal region
comparing the epileptic and stimulated side versus
the normal and non-stimulated side in the same
patient.1,2 We described that subacute electrical
stimulation of PHC is more effective in producing
antiepileptic effects in patients with less severe
epilepsy, an effect associated with higher GABA
tissue content and a low rate of cell loss, but with-
out changes in GABAA and benzodiazepine receptor
binding in PHC.3
Experimental evidences support the involvement
of opioid peptides in ictal, postictal and interictal
activity.4—10 Positron Emission Tomography (PET)
studies revealed that the epileptogenic hippocam-
pus from patients with MTLE shows reduced mu and
delta receptor binding whereas the lateral temporal
cortex of these patients, an area proposed to play
an important role in the seizure expression and
propagation, demonstrates an increase and non-
significant changes of mu and delta receptors,
respectively.11,12
The major purpose of the present study was the
characterization of mu, delta and nociceptin recep-
tor binding in PHC of patients with MTLEwho showed
antiepileptic effects after receiving subacute HFS in
this brain area. Clinical and electrophysiological
results obtained from these patients displaying anti-
epileptic effects during the HFS were previously
reported.1,2 Opioid receptor binding characteriza-
tion may improve the understanding of the patho-
physiology of a number of antiepileptic conditionsassociated with electrical stimulation, and it may
greatly enhance the safety and efficacy of this
therapy.Material and methods
Subject selection and brain samples
PHC tissue was obtained from patients with intract-
able MTLE history who underwent extensive preo-
perative phased evaluation in order to define focal
areas of maximal epileptogenesis. None of the
patients involved in the present study demonstrated
gross structural lesions, such as tumors or vascular
malformations. Table 1 provides a summary of the
relevant clinical data and side of the epileptic focus
for each patient.
HFS was applied in patients who, on the basis of
history and neurological examination, were felt to
be potential candidates, i.e. patients suffering
from intractable complex partial seizures in whom
invasive and non-invasive diagnostic procedures
allowed to localize unilateral MTLE. Further details
about the criteria for patient selection, electrode
implantation, clinical characteristics and temporal
lobectomy were previously reported.1,2 This
study was approved by the scientific committees
of the institutions involved in the present research
and informed consent was obtained from each
patient.
Patients were divided into four groups as follows:a) MTLE without HFS (MTLE group): four patients
(mean age 29.5  1.7 years old) with intractable
temporal lobe epilepsy history of 17.2  1.3
years and seizure frequency of 63  45 per
month had ‘‘en block’’ anterior lobectomy, ipsi-
lateral to the epileptic focus. Magnetic reso-
nance imaging (MRI) demonstrated mesial
sclerosis in every one of these patients (Table 1).b) MTLE plus HFS with antiepileptic effects (ESAE
group): five patients (mean age 27.8  1.9 years
old) with intractable temporal lobe epilepsy his-
tory of 14.8  2.5 years and seizure frequency of
11  2.9 per month underwent electrode
implantation which was performed as follows:
multicontact electrode grids were unilaterally
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Table 1 Characteristics of patients with MTLE with and without subacute HFS
Patient Group Sex Age Seizure
onset (age)
Duration of
epilepsy (years)
Frequency
seizures (month)
AED MRI
EDL MTLE M 25 11 14 30 CBZ/VA MS
CBC MTLE M 33 14 19 200 CBZ MS
JLUA MTLE M 29 13 16 12 CBZ/VA MS
ACMR MTLE F 31 11 20 10 CBZ/VA MS
MTP ESAE F 25 11 14 3 CBZ/PRIM N
FVA ESAE F 29 12 17 10 CBZ/VA MS
PMA ESAE F 25 17 8 15 CBZ/VA N
AAM ESAE M 35 12 23 20 PHT/GBP MS
CVA ESAE F 25 13 12 7 CBZ/GBP N
GAJL ESWAE M 42 14 28 10 CBZ/PHT MS
IRB ESWAE M 31 8 23 71 VA/GBP MS
JMSR ESWAE M 26 4 22 20 CBZ/PRIM MS
KSC ESWAE F 24 10 14 12 CBZ/PRIM MS
MTLE, patients with mesial temporal lobe epilepsy without HFS; ESAE, patients with MTLE plus HFS and presenting antiepileptic
effects; ESWAE, patients with MTLE plus HFS without antiepileptic effects; AED, antiepileptic drugs; CBZ, carbamazepine; VA,
valproic acid; PRIM, primidone; PHT, phenytoin; GBP, gabapentin; MS, mesial sclerosis; N, normal; MRI, magnetic resonance imaging.implanted at the pial surface of the basotemporal
cortex through a wide temporal craniotomy to
determine by electrocorticography the precise
site and extent of the focus, followed by HFS in
PHC during 16—20 days. Antiepileptic drugs were
discontinued 48—74 h prior to electrical stimula-
tion initiation as a conventional procedure to
activate and localize the epileptic focus.13 HFS
was delivered by a pulse generator (model DBS,
Medtronic Neurological, Minneapolis, MN, USA)
attached to AD-TECH externalized connectors.1
Stimuli consisted of continuous stimulation with
biphasic Lilly wave pulses 130 per second in fre-
quency, 450 ms in duration and 200—400 mA in
amplitude. Lilly wave pulses is a type of electrical
wave form which can be applied chronically for
several months without causing detectable injury
and significant changes in threshold.14 The relia-
bility of stimulation was daily determined by
measurements of voltage, impedance and current
flow at the intracerebral contacts throughout
externalized electrode systems. Stimulation was
interrupted only 1 h/day while EEG recordings
were taken. Patients from this group showed sig-
nificant decrease of interictal spike frequency
(no. of spikes in 10 s) and number of seizures
per day during the electrical stimulation.1,2 MRI
confirmed mesial sclerosis in two (40%) of these
patients. Although this group showed a favorable
response to the HFS, at present this procedure is
not an official therapeutic approach. Then, at the
completion of the clinical EEG and stimulation
studies, patients underwent a second surgery in
order to remove electrodes and carry out an ‘‘en
block’’ anterior lobectomy, ipsilateral to the epi-
leptic focus and PHC stimulation (Table 1).c) MTLE plus HFS without antiepileptic effects
(ESWAE group): four patients (mean age
30.7  4 years old) with intractable temporal
lobe epilepsy history of 21.7  2.8 years and
seizure frequency of 28.2  14 per month were
manipulated as it was described for ESAE group.
No significant changes in seizure occurrence and
interictal spikes frequency throughout the appli-
cation of HFS were observed in this group. MRI
established mesial sclerosis in the four patients
(100%) of this group (Table 1).d) Controls (C): control (n = 4) samples were
obtained from three male subjects (right and
left PHC samples were obtained from one sub-
ject) ranged in age from 20 to 30 years who
died by sudden and violent causes (vehicle
accident) and without history of neurological
disease. Control samples were dissected at the
time of autopsy, with a post mortem interval
(PMI) of 2—3 h after death, immediately stored
at 70 8C and then manipulated as described
below.Tissue preparation and histopathology
During the surgical procedure, PHC biopsies were
collected immediately upon resection, quickly fro-
zen in pulverized dry ice and stored at 70 8C.
Frozen sections of 20 mm were cut in a cryostat,
thaw-mounted on gelatin-coated slides, and stored
at 70 8C. Serial and parallel slides were obtained
for histological analysis as well as for autoradiogra-
phy (see below). Sections for histopathology were
cresyl violet-stained. The average cell density per
unit volume was determined by counting them
under a light microscope equipped with a digitalized
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Table 2 Conditions for autoradiography experiments
Receptor Ligand S.A. (nM) Buffer pH 7.6 Incubation,
RT (min)
Exposition,
RT (weeks)
Non-labeled
ligand (1 mM)
Reference
Mu 3H-DAMGO (2 nM)
55 Ci/mmol
Tris—HCl 50 mM 60 8 Naloxone 17
Delta 3H-DPDPE (10 nM)
40.7 Ci/mmol
Tris—HCl 50 mM 60 16 Naloxone 18
Nociceptin 3H-nociceptin (0.4 nM)
90 Ci/mmol
Tris—HCl 50 mM,
0.9% NaCl, 3 mM
MgC,l 0.2 mM EGTA,
1.26  103 U/l of
Bacitracin, BSA 0.1%
180 8 Nociceptin 19
S.A.: specific activity; RT: room temperature.image analysis system, and according with the pro-
cedure described previously.15,16
Autoradiography for mu, delta and
nociceptin receptor binding
The autoradiography experiments were carried out
on adjacent sections thaw-mounted on gelatin-
coated slides according to the procedures described
previously.17—19 Experimental conditions for mu,
delta and nociceptin autoradiography are summar-
ized in Table 2. The brain sections were initially
washed. Then, they were incubated in a solution
containing the specific 3H-ligand. Binding obtained
in the presence of a non-labeled ligand was consid-
ered to be nonspecific. Values of the specific binding
reported in the present study were obtained from
the difference between nonspecific and total bind-
ing. Finally, incubation was terminated with two
consecutive washes (1 min each) in buffer and a
distilled water rinse (2 s) at 4 8C. The sections were
quickly dried under a gentle stream of cold air, and
then they were arrayed in X-ray cassettes and
apposed to tritium-sensitive film together with tri-
tium standards (Amersham) at room temperature.
Thereafter, they were developed using standard
Kodak developer (D-11) and fast fixer at room tem-
perature. Optical densities were determined using a
video-computer enhancement program (JAVA Jan-
del Video Analysis Software). For each PHC, 10
optical density readings were taken from at least
five sections over the entire region resected, and
were averaged. The optical density readings of the
standards were used to determine tissue radioac-
tivity values for the accompanying tissue sections
and to convert them to fmol/mg protein.
Analysis of results and statistics
Receptor binding and cell count were examined
statistically by analysis of variance (ANOVA) and apost-hoc Tukey test to determine significant differ-
ences. Since receptor binding values do not further
allow assumptions on the exact receptor binding
changes in areas with decreased cell density, pro-
portions between receptor binding and cell count
([fmol/mg protein]/cell count) were obtained for
each 3H-ligand and experimental group. Finally,
Pearson correlation coefficients were calculated
to establish a significant correlation between recep-
tor binding and neuronal cell counts. A significant
correlation indicates that binding changes could be
influenced by the cell density, whereas absence of
correlation supports that binding alterations depend
on receptor characteristics.Results
Cell density and opioid receptor binding in
control PHC
The cell density in PHC obtained at autopsy from
subjects with no evidence of neurological disease
was 37,604  1769 cells/mm3. Autoradiography
experiments revealed 3H-DAMGO (18.1  2 fmol/
mg protein), 3H-DPDPE (81  11.6 fmol/mg protein)
and 3H-nociceptin (90.2  27.1 fmol/mg protein)
binding widely distributed in control PHC.
Cell density and opioid receptor binding in
epileptic PHC
Histopathology evaluation revealed decreased cell
count values in the PHC of the different epileptic
groups (MTLE, 70%, p < 0.05; ESAE, 48.8%, p < 0.05;
ESWAE, 72%, p < 0.05), when compared with control
samples. However, ESAE group demonstrated signif-
icantly higher values (58.5%, p < 0.05) in contrast
with MTLE group (Fig. 1).
Quantification of receptor binding by autoradio-
graphy experiments demonstrated augmented
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Figure 1 Total number of neurons in PHC of control
tissue (A), MTLE group (B) and from patients with MTLE
plus HFS with (ESAE group, C) and without antiepileptic
effects (ESWAE group, D). Density of neurons (mean-
s  S.E.M.) are expressed cell count per cubic millimeter.
*p < 0.05 vs. A; @p < 0.05 vs. B.3H-DAMGO binding in PHC of all epileptic groups
(MTLE, 113%, p < 0.05; ESAE, 109%, p < 0.05;
ESWAE, 89%, n.s.). Concerning 3H-DPDPE binding,
MTLE and ESAE groups showed values similar toFigure 2 3H-DAMGO (mu), 3H-DPDPE (delta) and 3H-nocice
between these receptor binding values and cell count (right), o
and from patients with MTLE plus electrical stimulation with
group, D). Binding values are expressed as mean  S.E.M. ofthose detected in control PHC samples, whereas
ESWAE group exhibited a non-significant enhance-
ment (35%). PHC from all epileptic groups demon-
strated high 3H-nociceptin binding (MTLE, 165%,
p < 0.05; ESAE, 97%, p < 0.05; ESAWE, 139%,
p < 0.05). However, ESAE group showed lower 3H-
nociceptin binding when compared with MTLE
group (25%, p < 0.05) (Fig. 2).
The analysis of proportions between receptor
binding and cell count revealed high 3H-DAMGO
(MTLE, 755%; ESAE, 375%; ESWAE, 693%), 3H-DPDPE
(MTLE, 242%; ESAE, 80%; ESWAE, 346%) and 3H-noci-
ceptin (MTLE, 424%; ESAE, 217%; ESWAE, 451%)
binding in PHC of all epileptic patients. Neverthe-
less, the tissue obtained from ESAE group demon-
strated lower values (3H-DAMGO, 44.5%, p < 0.05;
3H-DPDPE, 47%, p < 0.05; 3H-nociceptin, 39.3%,
p < 0.5) when compared with MTLE group (Fig. 2).
Non-significant correlations were found between
the cell density values and the 3H-DAMGO, 3H-DPDPE
and 3H-nociceptin binding evaluated for the differ-
ent epileptic groups (Table 3).ptin (nociceptin) receptor binding (left), and proportion
btained from PHC of control specimens (A), MTLE group (B)
(ESAE group, C) and without antiepileptic effects (ESWAE
fmol/mg of protein. *p < 0.05 vs. A; @p < 0.05 vs. B.
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Table 3 Cell/receptor binding correlations
Receptor MTLE ESAE ESWAE
Mu 0.690 0.601 0.642
Delta 0.745 0.526 0.624
Nociceptin 0.555 0.432 0.593
The values represent the Pearson correlation coefficients.Discussion
The PHC is a region which has been suggested to play
an important role in the intractable MTLE.20 Our
experiments revealed a significant decrease in the
neuronal count and high mu, delta and nociceptin
receptor binding in the surviving neurons of PHC of
patients with MTLE. The absence of correlation
between the reduced cell count and the receptor
binding indicates that the opioid receptor binding
alterations depend on changes in the receptor affi-
nity or number, rather than the cell density.
Frost et al.11 and Mayberg et al.12 described an
increase and non-significant changes of mu and
delta receptors, respectively, in temporal cortex
of patients with MTLE. In contrast with these
reports in which PET was used to evaluate opioid
receptor binding in vivo, the present study high-
lights a significant enhancement in mu, delta and
nociceptin opioid receptor binding taking into
account the cell loss. This situation could contri-
bute to the debate concerning the role of opioid
receptors in epilepsy.
Certainly, mu and delta receptors are also
expressed in glial cells21,22 and opioid peptides
may enhance their constitutive expression,23 lead-
ing to suggest that enhanced gliosis may account for
the high opioid receptor binding detected in PHC of
patients with MTLE. However, it is necessary to
consider that neuronal loss and gliosis may variably
be present in the epileptic cortex.24 In addition,
within the abnormal cortex the most remarkable
features are the presence of apoptotic bodies and
the filling up by dendritic and axonal process, but
not by glial process, of empty spaced left by the
neurons that had disappeared.25 This situation sug-
gests that the high opioid receptor binding detected
in PHC of epileptic patients must result from neu-
ronal opioid receptor changes.
A critical factor for the present study is the
postmortem delay that may modify the physical
conditions of the tissue considered accurate reflec-
tion of control situation. Previously, it was demon-
strated that at room temperature mu and delta
receptor binding was significantly reduced within
12 h but not at 6 h postmortem.26 Concerning noci-
ceptin receptors, 3H-nociceptin ligand binding and
nociceptin opioid receptor mRNA expression arewell preserved in the human brain with a postmor-
tem interval of 6—29.5 h.27 For the present study,
control values can be considered acceptable and
valid for analysis because autopsy control samples
were collected from 2 to 3 h after death and imme-
diately stored at 70 8C.
Some characteristics of the epileptic patients
could be associated with the antiepileptic effect
induced by HFS. When compared with the non-
responding patients (ESWAE group), the responding
patients (ESAE group) were younger, with a shorter
seizure history, smaller seizure frequency, lower
incidence of mesial temporal sclerosis, higher GABA
tissue content and reduced cell loss in the PHC.3
Further studies are necessary to elucidate if the
smaller increases of opioid receptor binding in
PHC represent an intrinsic characteristic of the
patients susceptible to present anticonvulsant
effects induced by HFS, or it is a consequence of
the repetitive exposure to the endogenous opioids
released by HFS.28,29 In addition, the lower suscept-
ibility to the HFS-induced antiepileptic effects of
patients with higher opioid receptor binding in PHC
(ESWAE group) supports the notion that the activa-
tion of mu, delta and nociceptin opioid receptors
facilitates the seizure activity.8—10,30—34
The enhanced activation or release of inhibitory
neurotransmitters such as GABA has been proposed
as a mechanism of HFS to induce inhibitory
effects.35,36 On the other hand, the activation of
mu, delta and nociceptin opioid receptors can inhi-
bit GABA release resulting in the suppression of the
GABA-mediated synaptic transmission.31,37,38 It is
possible that the GABA-mediated inhibitory effects
induced by HFS are facilitated in the PHC of the
responding patients that present a smaller increase
of opioid receptors.
Our experiments revealed that patients
responding to the HFS demonstrated less rate of
cell damage in PHC. It is described that HFS mimics
the effects of ablative procedures, considered as
inhibitory.39 In fact, chronic HFS produces an
effect analogous to that seen after lesions.40 It
is interesting to note that cerebral insults asso-
ciated with nervous tissue lesions result in
decreased mu and delta opioid receptors.41,42 It
is possible that the ‘‘lesion’’ effects induced by HFS
reduce the increased mu and delta receptor bind-
ing in PHC of epileptic patients. Concerning noci-
ceptin receptor binding, its activation enhances
excitotoxic lesions, an effect augmented by the
activation of mu receptors.43 Experiments should
be carried out to further investigate if the elevated
opioid receptor binding is associated with the high
cell loss detected in PHC of non-responding
patients.
Parahippocampal electrical stimulation and opioid receptors 651Finally, the results obtained lead to suggest that
the non-invasive characterization of the cerebral
opioid receptors and potentially epileptogenic
lesions including mesial temporal sclerosis, using
techniques such as PET and MRI, may become clini-
cally useful in the initial selection of candidate
epileptic patients to receive electrical stimulation
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